In vitro, the exposure of BRCA1 and BRCA2 mutated cancer cells to cisplatin or PARPis favors the development of secondary genetic changes on the mutated allele which restore a functional protein and confer platinum and PARPis resistance [26,27]. This evidence concerns the gene BRCA1 and cancer.